AstraZeneca plc (LON:AZN)‘s stock had its “overweight” rating reissued by equities researchers at Barclays PLC in a note issued to investors on Wednesday. They presently have a GBX 6,300 ($83.10) price objective on the biopharmaceutical company’s stock. Barclays PLC’s price objective suggests a potential upside of 37.89% from the stock’s previous close.

A number of other equities research analysts have also recently commented on AZN. UBS AG set a GBX 5,150 ($67.93) price target on shares of AstraZeneca plc and gave the stock a “neutral” rating in a report on Wednesday, April 5th. J P Morgan Chase & Co restated a “neutral” rating on shares of AstraZeneca plc in a report on Friday, July 21st. Shore Capital restated a “sell” rating on shares of AstraZeneca plc in a report on Sunday, April 2nd. Liberum Capital restated a “buy” rating and issued a GBX 5,500 ($72.55) price target on shares of AstraZeneca plc in a report on Wednesday, June 14th. Finally, BNP Paribas restated a “neutral” rating on shares of AstraZeneca plc in a report on Friday, July 21st. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of GBX 5,085.05 ($67.08).

Shares of AstraZeneca plc (LON AZN) traded up 1.95% during trading on Wednesday, reaching GBX 4569.00. 4,251,800 shares of the company were exchanged. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00. The stock’s 50-day moving average is GBX 5,140.37 and its 200-day moving average is GBX 4,862.43. The firm’s market cap is GBX 57.84 billion.

TRADEMARK VIOLATION WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.watchlistnews.com/barclays-plc-reiterates-overweight-rating-for-astrazeneca-plc-lonazn/1462082.html.

In related news, insider Nazneen Rahman acquired 39 shares of the stock in a transaction on Thursday, July 27th. The shares were acquired at an average price of GBX 4,370 ($57.64) per share, with a total value of £1,704.30 ($2,248.12).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.